Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions

This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with CHB treated with Nucleos(t)ide Analogue (NAs).

Participants needed: 70
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: AusperBio Therapeutics Inc.Updated: Jun 17, 2026Locations: 9
Eligibility criteria

Adults ≥18 years of age and up to 65 years of age (inclusive) at Screening who a... [+9]

Clinically significant disease other than chronic hepatitis B virus (HBV) infect... [+24]

Read more
Status: Recruiting

Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region

This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with Nucleos(t)ide Analogue (NAs).

Participants needed: 84
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: AusperBio Therapeutics Inc.Updated: Jun 1, 2026Locations: 8
Eligibility criteria

Adults ≥18 years of age (or per local age of majority) and ≤65 years of age at S... [+10]

Clinically significant disease other than chronic hepatitis B virus (HBV) infect... [+30]

Read more
Status: Not yet recruiting

Study of AHB-171 in Chronic Hepatitis B Participants

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AHB-171 in participants with chronic hepatitis B (CHB). Study advancement to subsequent parts/cohorts will require satisfactory interim reviews of available cumulative safety data by the Safety Review Committees (SRC), using the safety criteria and review procedures described in the protocol.

Participants needed: 144
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: AusperBio Therapeutics Inc.Updated: Jun 1, 2026Locations: 2
Eligibility criteria

Male or female participants, aged 18-65 years old (inclusive) [+9]

Significant medical conditions other than chronic HBV (e.g. recent heart issues,... [+18]

Read more